{"issuance_frequency":"","notes_translated":{"fr":"Le présent document fournit des directives sur l'étude et l'analyse des différences liées au sexe dans les essais cliniques relatifs aux produits thérapeutiques. Il vise également à produire des données probantes pour permettre d'offrir des conseils sur l'usage optimal des produits thérapeutiques chez les femmes et les hommes.","en":"This document provides guidance on the study and analysis of sex differences in clinical trials of therapeutic products in order to generate evidence to advise on the optimal use of therapeutic products in both women and men."},"issn":"","imso_approval":"true","isbn":"","creator":"","org_section":{"fr":"","en":""},"jurisdiction":"federal","private":false,"maintainer_email":"open-ouvert@tbs-sct.gc.ca","num_tags":0,"edition":"","frequency":"as_needed","data_series_issue_identification":{"fr":"","en":""},"contributor":{"fr":"","en":""},"maintainer":null,"ready_to_publish":"true","id":"1e2d8da6-f1a4-4678-b593-7df16d428c2e","metadata_created":"2020-09-17T20:21:12.479558","subject":["health_and_safety"],"pspc_identification_number":"","metadata_modified":"2020-09-17T20:21:12.479564","author":null,"author_email":null,"geographic_region":[],"portal_release_date":"2020-09-17","digital_object_identifier":"","state":"active","version":null,"keywords":{"fr":["inclusion des femmes dans les essais cliniques","analyse des données selon le sexe dans les essais cliniques","produits thérapeutiques","usage optimal des produits thérapeutiques chez les femmes et les hommes"],"en":["Inclusion of Women in Clinical Trials","analysis of sex differences in clinical trials","therapeutic products","optimal use of therapeutic products in both women and men."]},"relationships_as_object":[],"creator_user_id":"4cfa9a9c-1d95-40eb-86f9-bc0c8ec45d1f","title_translated":{"fr":"Document d'orientation : Considérations relatives à l'inclusion des femmes dans les essais cliniques et à l'analyse des données selon le sexe","en":"Guidance Document: Considerations for Inclusion of Women in Clinical Trials and Analysis of Sex Differences"},"type":"info","resources":[{"cache_last_updated":null,"unique_identifier":"","package_id":"1e2d8da6-f1a4-4678-b593-7df16d428c2e","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"460ac10f-f801-4dc3-8314-8f4a9d1b1f02","related_relationship":"","name_translated":{"fr":"Document d'orientation : Considérations relatives à l'inclusion des femmes dans les essais cliniques et à l'analyse des données selon le sexe","en":"Guidance Document: Considerations for Inclusion of Women in Clinical Trials and Analysis of Sex Differences"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance Document: Considerations for Inclusion of Women in Clinical Trials and Analysis of Sex Differences","language":["en"],"created":"2020-09-17T20:21:12.595334","url":"https://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/applications-submissions/guidance-documents/considerations-inclusion-women-clinical-trials.html","last_modified":null,"position":0,"revision_id":"6e036f2e-b84d-478c-a51c-3b69e932e514","resource_type":"publication"},{"cache_last_updated":null,"unique_identifier":"","package_id":"1e2d8da6-f1a4-4678-b593-7df16d428c2e","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"5c37c25f-f0dc-4d87-9f23-2f5db3a43eab","related_relationship":"","name_translated":{"fr":"Document d'orientation : Considérations relatives à l'inclusion des femmes dans les essais cliniques et à l'analyse des données selon le sexe","en":"Guidance Document: Considerations for Inclusion of Women in Clinical Trials and Analysis of Sex Differences"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance Document: Considerations for Inclusion of Women in Clinical Trials and Analysis of Sex Differences","language":["fr"],"created":"2020-09-17T20:21:12.595341","url":"https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/produits-biologiques-radiopharmaceutiques-therapies-genetiques/information-demandes-presentations/lignes-directrices/considerations-relatives-inclusion-femmes-essais-cliniques-analyse.html","last_modified":null,"position":1,"revision_id":"6e036f2e-b84d-478c-a51c-3b69e932e514","resource_type":"publication"}],"place_of_publication":[],"num_resources":2,"tags":[],"spatial":"","collection":"publication","org_title_at_publication":{"fr":"Santé Canada","en":"Health Canada"},"date_published":"2017-05-04 00:00:00","issuance":"","groups":[],"license_id":"ca-ogl-lgo","data_series_name":{"fr":"","en":""},"relationships_as_subject":[],"license_title":"Open Government Licence - Canada","restrictions":"unrestricted","organization":{"description":"","created":"2016-09-23T17:25:33.001625","title":"Health Canada | Santé Canada","name":"hc-sc","is_organization":true,"state":"active","image_url":"","revision_id":"6a0471e8-36e5-4217-8f72-563c83e6465a","type":"organization","id":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","approval_status":"approved"},"name":"1e2d8da6-f1a4-4678-b593-7df16d428c2e","isopen":false,"additional_notes":{"fr":"","en":""},"departmental_identification_number":"","notes":"This document provides guidance on the study and analysis of sex differences in clinical trials of therapeutic products in order to generate evidence to advise on the optimal use of therapeutic products in both women and men.","owner_org":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","program_page_url":{"fr":"","en":""},"url":null,"audience":[],"gc_catalogue_number":"","license_url":"http://open.canada.ca/en/open-government-licence-canada","series_publication_dates":{"fr":"","en":""},"title":"Guidance Document: Considerations for Inclusion of Women in Clinical Trials and Analysis of Sex Differences","revision_id":"6e036f2e-b84d-478c-a51c-3b69e932e514"}